Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1140209

registered interest
date	18/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions there have been between Vertex Pharmaceuticals and NHS England with on cystic fibrosis medicines.
tabling member constituency	Bristol East
tabling member printed	Kerry McCarthy
uin	278928
answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278929 question first answered 23/07/2019 16:49:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	1491 label Biography information for Kerry McCarthy

1140210

registered interest
date	18/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will set a deadline for NHS England and Vertex Pharmaceuticals to come to an agreement to enable access to cystic fibrosis medicines produced by that company.
tabling member constituency	Bristol East
tabling member printed	Kerry McCarthy
uin	278929
answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>Discussions with Vertex, including meetings, are ongoing.</p><p>NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.</p><p>The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England’s and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 278928 question first answered 23/07/2019 16:49:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	1491 label Biography information for Kerry McCarthy

1140410

registered interest
date	18/07/2019
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Animal Experiments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Environment, Food and Rural Affairs, what steps he is taking to ensure that there is no duplication of animal testing for chemical registrations in the event that the UK leaves the EU without an agreement.
tabling member constituency	Bristol East
tabling member printed	Kerry McCarthy
uin	278930
answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>We are determined that there should be no need for any additional animal testing for a chemical that has already been registered to EU Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) if the UK leaves the EU without a deal. In such a scenario, the UK system that we will put in place (UK REACH) will retain the ‘last resort principle’ – that companies can only use animal testing as a last resort.</p><p> </p><p>We have also ensured that under UK REACH the information requirements would be the same as under EU REACH. Businesses will therefore be able to confirm their registrations by submitting the same technical information that was required by EU REACH.</p><p> </p><p> </p> answering member constituency Suffolk Coastal answering member printed Dr Thérèse Coffey question first answered 23/07/2019 15:42:32 answering member 4098 label Biography information for Dr Thérèse Coffey
tabling member	1491 label Biography information for Kerry McCarthy